{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=doxorubicin+hydrochloride&page=14", "query": { "intervention": "doxorubicin hydrochloride", "page": 14 }, "page_size": 10 }, "pagination": { "page": 14, "page_size": 10, "total_count": 1375, "total_pages": 138, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=doxorubicin+hydrochloride&page=15&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=doxorubicin+hydrochloride&page=13&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-17T17:08:34.423Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT06717347", "title": "A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Diffuse Large B-Cell Lymphoma" ], "interventions": [ { "name": "Zilovertamab vedotin", "type": "BIOLOGICAL" }, { "name": "Rituximab", "type": "BIOLOGICAL" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Doxorubicin", "type": "DRUG" }, { "name": "Rituximab Biosimilar", "type": "BIOLOGICAL" }, { "name": "Prednisone", "type": "DRUG" }, { "name": "Prednisolone", "type": "DRUG" }, { "name": "Vincristine", "type": "DRUG" }, { "name": "Rescue medication", "type": "DRUG" }, { "name": "Methylprednisolone", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Merck Sharp & Dohme LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1046, "start_date": "2025-01-27", "completion_date": "2032-03-29", "has_results": false, "last_update_posted_date": "2026-10-16", "last_synced_at": "2026-10-17T17:08:34.423Z", "location_count": 59, "location_summary": "Mobile, Alabama • Gilbert, Arizona • Phoenix, Arizona + 54 more", "locations": [ { "city": "Mobile", "state": "Alabama" }, { "city": "Gilbert", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Fullerton", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06717347" }, { "nct_id": "NCT05870748", "title": "REFRaME-O1: A Study to Investigate the Efficacy and Safety of Luveltamab Tazevibulin Versus Investigator's Choice (IC) Chemotherapy in Women With Ovarian Cancer (Including Fallopian Tube or Primary Peritoneal Cancers) Expressing FOLR1", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Ovarian Cancer", "Epithelial Ovarian Cancer", "Fallopian Tube Cancer", "Primary Peritoneal Cancer", "Platinum-resistant Ovarian Cancer" ], "interventions": [ { "name": "Luveltamab tazevibulin", "type": "DRUG" }, { "name": "Pegfilgrastim", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Pegylated liposomal doxorubicin", "type": "DRUG" }, { "name": "Topotecan", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sutro Biopharma, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 600, "start_date": "2023-07-12", "completion_date": "2025-08-26", "has_results": false, "last_update_posted_date": "2025-09-23", "last_synced_at": "2026-10-17T17:08:34.423Z", "location_count": 37, "location_summary": "Tucson, Arizona • Daly City, California • San Diego, California + 33 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Daly City", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Miami", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT05870748" }, { "nct_id": "NCT00001498", "title": "A Pilot Trial of Sequential Chemotherapy With Antimetabolite Induction, High-Dose Alkylating Agent Consolidation With Peripheral Blood Progenitor Cell Support, and Intensification With Paclitaxel and Doxorubicin for Patients With High-Risk Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Breast Cancer", "Breast Neoplasms" ], "interventions": [ { "name": "methotrexate", "type": "DRUG" }, { "name": "leucovorin", "type": "DRUG" }, { "name": "5-fluorouracil", "type": "DRUG" }, { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "peripheral blood progenitor cell", "type": "PROCEDURE" }, { "name": "paclitaxel", "type": "DRUG" }, { "name": "doxorubicin", "type": "DRUG" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 55, "start_date": "1996-02", "completion_date": "2000-12", "has_results": false, "last_update_posted_date": "2008-03-04", "last_synced_at": "2026-10-17T17:08:34.423Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00001498" }, { "nct_id": "NCT02584478", "title": "Phase 1/2a/3 Evaluation of Adding AL3818 to Standard Platinum-Based Chemotherapy in Subjects With Recurrent or Metastatic Endometrial, Ovarian, Fallopian, Primary Peritoneal or Cervical Carcinoma (AL3818-US-002)", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Endometrial Carcinoma", "Ovarian Carcinoma", "Fallopian Tube Carcinoma", "Primary Peritoneal Carcinoma", "Cervical Carcinoma" ], "interventions": [ { "name": "AL3818", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Pegylated Liposomal Doxorubicin (PLD)", "type": "DRUG" }, { "name": "Topotecan", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Advenchen Laboratories, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 294, "start_date": "2015-12", "completion_date": "2024-12", "has_results": false, "last_update_posted_date": "2023-11-08", "last_synced_at": "2026-10-17T17:08:34.423Z", "location_count": 8, "location_summary": "Long Beach, California • Miami, Florida • Lexington, Kentucky + 5 more", "locations": [ { "city": "Long Beach", "state": "California" }, { "city": "Miami", "state": "Florida" }, { "city": "Lexington", "state": "Kentucky" }, { "city": "St Louis", "state": "Missouri" }, { "city": "The Bronx", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT02584478" }, { "nct_id": "NCT05711615", "title": "Testing Low-Dose Common Chemotherapy (Liposomal Doxorubicin) in Combination With an Anti-Cancer Drug, Peposertib, in Advanced Sarcoma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Metastatic Dedifferentiated Liposarcoma", "Metastatic Leiomyosarcoma", "Metastatic Myxofibrosarcoma", "Metastatic Sarcoma", "Metastatic Synovial Sarcoma", "Metastatic Undifferentiated Pleomorphic Sarcoma", "Unresectable Dedifferentiated Liposarcoma", "Unresectable Leiomyosarcoma", "Unresectable Myxofibrosarcoma", "Unresectable Sarcoma", "Unresectable Synovial Sarcoma", "Unresectable Undifferentiated Pleomorphic Sarcoma" ], "interventions": [ { "name": "Biopsy Procedure", "type": "PROCEDURE" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Echocardiography Test", "type": "PROCEDURE" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Multigated Acquisition Scan", "type": "PROCEDURE" }, { "name": "Pegylated Liposomal Doxorubicin Hydrochloride", "type": "DRUG" }, { "name": "Peposertib", "type": "DRUG" } ], "intervention_types": [ "PROCEDURE", "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 30, "start_date": "2024-02-06", "completion_date": "2026-11-03", "has_results": false, "last_update_posted_date": "2026-09-04", "last_synced_at": "2026-10-17T17:08:34.423Z", "location_count": 16, "location_summary": "Los Angeles, California • Aurora, Colorado • Miami, Florida + 11 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Miami", "state": "Florida" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT05711615" }, { "nct_id": "NCT01100944", "title": "A Phase 1/2 Study of PXD101 (Belinostat) in Combination With Cisplatin, Doxorubicin and Cyclophosphamide in the First Line Treatment of Advanced or Recurrent Thymic, Malignancies", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Thymoma", "Thymic Carcinoma" ], "interventions": [ { "name": "PXD101with cisplatin+doxorubicin+cyclophosphamide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "100 Years", "sex": "ALL", "summary": "18 Years to 100 Years" }, "enrollment_count": 26, "start_date": "2010-03-04", "completion_date": "2015-10-21", "has_results": true, "last_update_posted_date": "2017-08-10", "last_synced_at": "2026-10-17T17:08:34.423Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT01100944" }, { "nct_id": "NCT01215344", "title": "First Autologous Transplant on Minimal Residual Disease Markers in Previously Untreated Myeloma Undergoing Initial Treatment With Velcade", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Multiple Myeloma" ], "interventions": [ { "name": "VELCADE", "type": "DRUG" }, { "name": "Lenalidomide", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" }, { "name": "DVT prophylaxis", "type": "DRUG" }, { "name": "Bisphosphonates", "type": "DRUG" }, { "name": "Liposomal doxorubicin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Vanderbilt-Ingram Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 36, "start_date": "2010-11", "completion_date": "2018-03", "has_results": true, "last_update_posted_date": "2018-05-15", "last_synced_at": "2026-10-17T17:08:34.423Z", "location_count": 2, "location_summary": "Memphis, Tennessee • Nashville, Tennessee", "locations": [ { "city": "Memphis", "state": "Tennessee" }, { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT01215344" }, { "nct_id": "NCT00742404", "title": "Doxorubicin Hydrochloride Liposome, Bortezomib, and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Multiple Myeloma and Plasma Cell Neoplasm" ], "interventions": [ { "name": "bortezomib", "type": "DRUG" }, { "name": "dexamethasone", "type": "DRUG" }, { "name": "pegylated liposomal doxorubicin hydrochloride", "type": "DRUG" }, { "name": "protein analysis", "type": "GENETIC" }, { "name": "immunologic technique", "type": "OTHER" } ], "intervention_types": [ "DRUG", "GENETIC", "OTHER" ], "sponsor": "Oncotherapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 35, "start_date": "2008-07", "completion_date": null, "has_results": false, "last_update_posted_date": "2013-12-18", "last_synced_at": "2026-10-17T17:08:34.423Z", "location_count": 12, "location_summary": "Tucson, Arizona • Bakersfield, California • Escondido, California + 9 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Bakersfield", "state": "California" }, { "city": "Escondido", "state": "California" }, { "city": "Loma Linda", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00742404" }, { "nct_id": "NCT05630209", "title": "Blood Brain Barrier (BBB) Disruption Using Exablate Focused Ultrasound With Doxorubicin for Treatment of Pediatric Diffuse Intrinsic Pontine Gliomas (DIPG)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Brain Tumor" ], "interventions": [ { "name": "Exablate", "type": "DEVICE" }, { "name": "Doxorubicin", "type": "DRUG" } ], "intervention_types": [ "DEVICE", "DRUG" ], "sponsor": "InSightec", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "5 Years", "maximum_age": "21 Years", "sex": "ALL", "summary": "5 Years to 21 Years" }, "enrollment_count": 10, "start_date": "2023-01-04", "completion_date": "2026-10", "has_results": false, "last_update_posted_date": "2026-04-17", "last_synced_at": "2026-10-17T17:08:34.423Z", "location_count": 3, "location_summary": "Washington D.C., District of Columbia • Miami, Florida • Fort Worth, Texas", "locations": [ { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Miami", "state": "Florida" }, { "city": "Fort Worth", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT05630209" }, { "nct_id": "NCT05605899", "title": "Study to Compare Axicabtagene Ciloleucel With Standard of Care Therapy as First-line Treatment in Participants With High-risk Large B-cell Lymphoma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "High-risk Large B-cell Lymphoma (LBCL)" ], "interventions": [ { "name": "Axicabtagene Ciloleucel", "type": "BIOLOGICAL" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "Etoposide", "type": "DRUG" }, { "name": "Rituximab", "type": "DRUG" }, { "name": "Doxorubicin", "type": "DRUG" }, { "name": "Vincristine", "type": "DRUG" }, { "name": "Prednisone", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Kite, A Gilead Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 300, "start_date": "2023-02-10", "completion_date": "2031-03", "has_results": false, "last_update_posted_date": "2026-04-15", "last_synced_at": "2026-10-17T17:08:34.423Z", "location_count": 32, "location_summary": "Birmingham, Alabama • Gilbert, Arizona • Phoenix, Arizona + 26 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Gilbert", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05605899" } ] }